Just the Facts: Tryptamine Therapeutics advances TRP-8803 to Phase 2 Clinical Trials

Proactive - Interviews for investors

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF). Tryp has completed its Phase 1b clinical study for TRP-8803, a psilocin-based IV-infusion formulation, successfully meeting all key objectives. These results enable the company to proceed to Phase 2 clinical trials. TRP-8803 presents several advantages over oral psilocybin, including faster onset (under 20 minutes), precise control over treatment duration and enhanced safety, particularly the ability to halt treatment in the event of adverse reactions. The Phase 1b study demonstrated TRP-8803’s safety across low, mid and high dose levels, identified optimal doses and infusion rates, and achieved consistent therapeutic blood levels of psilocin. All 11 participants experienced rapid onset of the psychedelic state compared to the longer duration of oral psilocybin treatments, with the Safety Review Council confirming the treatment was safe and well-tolerated. The study generated a comprehensive dataset to inform the design of future trials. TRP-8803 is positioned as a scalable solution for achieving neuroplastic benefits, offering potential structural and functional brain improvements. Tryptamine plans to collaborate with research partners to further explore psilocin’s therapeutic potential, advancing its clinical development pathway in the growing field of psychedelic medicine. #ProactiveInvestors #TryptamineTherapeutics #ASX #JusttheFacts #TRP8803, #Psilocin, #IVInfusion, #Phase2Trials, #ClinicalResearch, #PsychedelicMedicine, #Neuroplasticity, #MentalHealth, #DrugDevelopment, #SafetyInMedicine, #BrainHealth, #PsilocybinAlternative, #TherapeuticInnovation, #HealthOutcomes, #PsychedelicResearch, #MentalHealthInnovation, #Pharmacology, #EmergingMedicine, #ClinicalBreakthrough